key: cord-0695074-05p5pwm4
authors: Kessel, Aharon; Bamberger, Ellen; Nachshon, Liat; Rosman, Yossi; Confino‐Cohen, Ronit; Elizur, Arnon
title: Safe administration of the Pfizer‐BioNtTech COVID‐19 vaccine following an immediate reaction to the first dose
date: 2021-08-16
journal: Allergy
DOI: 10.1111/all.15038
sha: 1ca1135804cf9b54038b49fa4e20ca1273e82d23
doc_id: 695074
cord_uid: 05p5pwm4

nan

Eighteen patients with a mean age of 54.3 years (range, 23-75) were included (Table 1) . Mean time interval from PBV receipt to symptoms onset was 28.9 min (range, 5-60 min). Eleven (63.2%) patients had non-anaphylactic immediate reactions, and seven patients (36.8%) experienced anaphylaxis. None had hypotension or syncope. Fifteen patients underwent SPT to PBV and sixteen underwent SPT and ID tests to Methylprednisolone, which were all negative ( Table 2 ). All patients received a second PBV dose, 12 following pretreatment with antihistamines. Four individuals had an immediate reaction after the second PBV dose, which was milder than the index reaction, and none required emergency room treatment or adrenaline.

COVID-19 has caused more than 3 million deaths and a worldwide economic crisis since its emergence in December 2019. 7 The newly developed vaccines provide hope for ending the pandemic. However, allergic reactions to the vaccine might impair this effort not only by preventing the administration of a 2nd dose but also by reducing compliance with the 1st dose. Still, those with a severe reaction received the second dose as well.

In conclusion, we suggest that routine SPT to the vaccine or to 

Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine

Maintaining safety with SARS-CoV-2 vaccines

mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose! Allergy

Online ahead of print

Brighton collaboration anaphylaxis working group

mRNA vaccines to prevent COVID 19 disease and reported allergic reactions: current evidence and suggested approach

Excess deaths associated with COVID-19, by age and race and ethnicity-United States

Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy